Industry
Biotechnology
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 26, 2024 | 8:07 pm
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 12:28 pm
Portfolio Pulse from Benzinga Newsdesk
July 25, 2024 | 4:14 pm
Portfolio Pulse from Benzinga Newsdesk
July 25, 2024 | 11:39 am
Portfolio Pulse from Benzinga Insights
March 27, 2024 | 1:25 pm
Portfolio Pulse from Benzinga Newsdesk
March 27, 2024 | 12:18 pm
Portfolio Pulse from Benzinga Newsdesk
March 27, 2024 | 11:15 am
Portfolio Pulse from Benzinga Newsdesk
March 27, 2024 | 11:14 am
Portfolio Pulse from Benzinga Insights
January 09, 2024 | 1:06 pm
Portfolio Pulse from Benzinga Newsdesk
December 08, 2023 | 5:43 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.